Healthtech startup ErlySign has secured INR 16 Cr (around $1.8 Mn) in Pre-Series A funding round from Ashish Kacholia to further develop its cancer diagnostic solutions.

The fresh proceeds will be deployed in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market, the startup said in its statement.

“It will support research and development, team expansion, and further patent filings,” it added.

Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign or CURO Biosciences develops solutions for early detection of oral cancer.

The company also claims to offer India’s first salivary biomarker based test which can identify pre- cancerous conditions much before visible symptoms emerge.

The biomarker-based test kit can detect oral precancerous conditions within 15 minutes with a saliva sample to enable timely intervention.

“The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures,” said Thakur.

The development comes at a time when India’s healthcare space is gradually revamping with technological interventions, especially after Covid-19 pandemic.

According to Inc42’s ‘‘, healthtech startups raised a little over $7 Bn between 2014 and H1 2024 in 886 deals. However, the sector is making progress towards attracting investors’ interest lately and there’s an uptick in funding numbers.

The cumulative funding secured by healthtech startups jumped 2.8X to $460 Mn in the first half (H1) of 2024 from $120 Mn raised in H1 2023.

Recently, healthtech unicorn to transform healthcare with AI and cloud capabilities.

Last month, healthtech startup (around INR 25.5 Cr) in its seed funding round led by Together Fund.

The post appeared first on .